Centre National De La Recherche Scientifique

Universiteit Gent

Vib Vzw

Centre Hospitalier Régional Universitaire De Montpellier

Universitè De Montpellier

Universite Montpellier 2

Universität Osnabrück

Universite Montepellier 2

Franciane Paul

Jan Tavernier

Gilles Uze

Yann Bordat

Guillaume Cartron

Jacob Piehler

Gilles Uzé

Lennart Zabeau

Jennyfer Bultinck

Sarah Gerlo

Genevieve Garcin

Geneviève Garcin

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Fusokines involving cytokines with strongly reduced receptor binding affinities

This disclosure relates to a modified &#x3b1;-helical bundle cytokine, with reduced activity via an &#x3b1;-helical bundle cytokine receptor, wherein the &#x3b1;-helical bundle cytokine is specifically delivered to target cells. Preferably, the &#x3b1;-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified &#x3b1;-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified &#x3b1;-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.

Targeted and mutated human-interferon fusion proteins

The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.

Targeting of human interferon antagonists

Targeted human-interferon fusion proteins

Growing community of inventors

Montpellier, France

Franciane Paul